Dan Zandberg
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dan Zandberg sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Dan Zandberg: 9 sponsored US clinical trials, 3 recruiting.
Dan Zandberg sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 3 trials.
Top-decile sponsor footprint
Dan Zandberg ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
NCT06052839
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
NCT04114136
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
NCT04369937
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
NCT04074967
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
NCT04326257
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT04157985
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
NCT02777385
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
NCT02289209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 1 |
What is open in the Dan Zandberg pipeline
3 recruiting of 9 indexed (33% open); 4 completed (44%).
Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Melanoma (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dan Zandberg: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Dan Zandberg sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Dan Zandberg page
9 registered trials is a research-attention snapshot, not an endorsement of Dan Zandberg or any single study.
- 3 of Dan Zandberg's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma is the condition Dan Zandberg studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dan Zandberg pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.